Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalMarket CapitalizationReturn on AssetsReturn on Capital EmployedReturn on Equity

Fulcrum Therapeutics (FULC) EBITDA Margin: 2020-2024

Historic EBITDA Margin for Fulcrum Therapeutics (FULC) over the last 4 years, with Jun 2024 value amounting to 65.61%.

  • Fulcrum Therapeutics' EBITDA Margin rose 316698.00% to 65.61% in Q2 2024 from the same period last year, while for Jun 2024 it was -39.72%, marking a year-over-year increase of 349495.00%. This contributed to the annual value of -11.82% for FY2024, which is 343466.00% up from last year.
  • According to the latest figures from Q2 2024, Fulcrum Therapeutics' EBITDA Margin is 65.61%, which was up 102.04% from -3,213.78% recorded in Q4 2023.
  • Fulcrum Therapeutics' 5-year EBITDA Margin high stood at 65.61% for Q2 2024, and its period low was -9,471.19% during Q1 2023.
  • Its 3-year average for EBITDA Margin is -3,146.06%, with a median of -3,101.36% in 2023.
  • Its EBITDA Margin has fluctuated over the past 5 years, first crashed by 844,414bps in 2023, then skyrocketed by 316,698bps in 2024.
  • Over the past 5 years, Fulcrum Therapeutics' EBITDA Margin (Quarterly) stood at -420.19% in 2020, then plummeted by 5,023bps to -470.42% in 2021, then plummeted by 361,323bps to -4,083.65% in 2022, then soared by 86,987bps to -3,213.78% in 2023, then soared by 316,698bps to 65.61% in 2024.
  • Its last three reported values are 65.61% in Q2 2024, -3,213.78% for Q4 2023, and -3,615.28% during Q3 2023.